Institutional investors purchased a net $5.7 million shares of TXMD during the quarter ended September 2016. This may signal that the smart money is gaining interest in this company as the 79.15% of shares outstanding that institutional investors hold is actually below the Pharmaceuticals: Generic industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 1.8 Million shares of TherapeuticsMD Inc
CITADEL ADVISORS LLC Bought 1.5 Million shares of TherapeuticsMD Inc